(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -17.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Nektar Therapeutics's revenue in 2025 is $98,427,000.On average, 7 Wall Street analysts forecast NKTR's revenue for 2025 to be $13,514,470,353, with the lowest NKTR revenue forecast at $8,497,489,828, and the highest NKTR revenue forecast at $24,215,798,871. On average, 8 Wall Street analysts forecast NKTR's revenue for 2026 to be $11,472,727,889, with the lowest NKTR revenue forecast at $4,466,486,112, and the highest NKTR revenue forecast at $24,703,390,271.
In 2027, NKTR is forecast to generate $10,535,324,117 in revenue, with the lowest revenue forecast at $1,507,439,063 and the highest revenue forecast at $24,627,087,800.